GeoVax's Multi-Antigen COVID-19 Vaccine Shows Strong Immune Response in Immunocompromised Patients
TL;DR
GeoVax's GEO-CM04S1 vaccine outperforms standard mRNA vaccines in immunocompromised patients, offering a competitive edge in the multi-billion dollar underserved market.
GEO-CM04S1 uses a Modified Vaccinia Ankara vector to express both Spike and Nucleocapsid proteins, stimulating robust T-cell and cross-variant antibody responses.
This vaccine addresses urgent unmet needs for immunocompromised patients, making the world safer for vulnerable populations against COVID-19 variants.
GeoVax's multi-antigen approach generates durable immunity against Omicron subvariants, with an updated KP.2 construct advancing to trials in 2026.
Found this article helpful?
Share it with your network and spread the knowledge!
GeoVax Labs, Inc. presented positive interim clinical results for its COVID-19 vaccine candidate GEO-CM04S1 at the European Society of Clinical Microbiology and Infectious Disease Conference, showing strong immune responses in immunocompromised patients with blood cancers and chronic lymphocytic leukemia. The data, presented by Chief Medical Officer Kelly T. McKee, Jr., MD, MPH, revealed no serious adverse events attributed to the vaccine and demonstrated potent, durable T-cell and cross-variant antibody responses that exceed those of standard vaccines.
The clinical results are particularly significant because immunocompromised patients represent a multi-billion-dollar global market where first-generation COVID-19 vaccines have shown limited effectiveness. In the chronic lymphocytic leukemia trial interim analysis, GEO-CM04S1 met its primary endpoint while the comparator mRNA vaccine did not, prompting continuation solely in the GEO-CM04S1 arm. This competitive differentiation highlights the potential of GeoVax's multi-antigen approach to address urgent unmet medical needs.
GEO-CM04S1 is based on a Modified Vaccinia Ankara vector platform that expresses both the Spike and Nucleocapsid proteins of SARS-CoV-2, designed to stimulate robust humoral and cellular immunity. Unlike single-antigen vaccines, this multi-antigen approach has demonstrated durable immune responses and cross-variant protection, including activity against Omicron subvariants such as XBB.1.5. The vaccine is currently in three Phase 2 clinical trials evaluating its use as both a primary vaccine and booster in various patient populations.
David Dodd, Chairman and CEO of GeoVax, stated that these results underscore the value and competitive advantage of their vaccine platform. The company is already planning to advance an updated construct incorporating the Omicron KP.2 Spike gene, with clinical testing expected to begin in 2026. This positions GeoVax at the forefront of next-generation COVID-19 vaccine development while providing platform validation for broader applications across infectious diseases. For more information about the company's clinical programs, visit https://www.geovax.com.
Curated from NewMediaWire
